AMENDMENT UNDER 37 C.F.R. § 1.111

Attorney Docket No.: Q85706

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A galactosamine <u>derivative-compound</u> represented by the following formula (1):

wherein R_1 , R_2 and R_5 each independently represents SO_3^- or H, and at least one of them represents SO_3^- ;

R₃ represents H, acetyl or SO₃;

R₄ represents H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted acyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group;

X represents O, S, NH or CH₂; and

 \sim represents an α bond or a β bond, and

with the proviso that a compound in which R_1 and R_2 are H, R_5 is SO_3 , R_3 is an acetyl group, R_4 is a para-nitrophenyl group and X is O, and a compound in which R_1 , R_2 , and R_5 are each independently SO_3 or H, R_3 is H, an acetyl group or SO_3 , R_4 is a benzyl group and X is O, are excluded.

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/520,659

Attorney Docket No.: Q85706

2. (currently amended): The galactosamine derivative compound according to claim 1, wherein R_1 and R_2 each is H; R_3 is an acetyl group; R_4 is a substituted or unsubstituted aryl group; and R_5 is SO_3 , with the proviso that a compound wherein R_4 is a para-nitrophenyl group is excluded.

- 3. (currently amended): The galactosamine derivative compound according to claim 1, wherein R_1 is SO_3^- ; R_2 and R_5 each is H; R_3 is an acetyl group; and R_4 is a substituted or unsubstituted aryl group.
- 4. (currently amended): The galactosamine derivative compound according to claim 1, wherein R_1 and R_5 each is H; R_2 is SO_3^- ; R_3 is an acetyl group; and R_4 is a substituted or unsubstituted aryl group.
 - 5.-6. (canceled).
- 7. (withdrawn-currently amended): A method for inhibiting activity of a sulfotransferase, which comprises allowing the galactosamine derivative compound according to claim 1 to be present in an enzyme reaction system of the sulfotransferase.
 - 8.-9. (canceled).
- 10. (withdrawn-currently amended): A medicament based on inhibition of sulfotransferase activity, which comprises the galactosamine derivative compound according to claim 1 as an active ingredient.

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/520,659

Attorney Docket No.: Q85706

11. (withdrawn-currently amended): A medicament for treating or preventing diseases caused by acceleration of sulfotransferase activity, which comprises the galactosamine derivative compound according to claim 1 as an active ingredient.

12. (withdrawn-currently amended): A method for treating or preventing diseases caused by acceleration of sulfotransferase activity, which comprises administering to a subject in need thereof an effective amount of the glactosamine derivative compound according to claim 1.